Leendert Trouw

Has grant

Professor

Leiden University Medical Center

Netherlands

Research Interests

Explore related searches

Professors in Netherlands Professors in Immunology Immunology professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Leendert Trouw is a Professor at Leiden University Medical Center in the Netherlands. His research focuses on the roles of autoantibodies and complement system mechanisms in various autoimmune conditions, particularly systemic lupus erythematosus and rheumatoid arthritis. He has published extensively on topics such as the structural basis of complement activation and the clinical implications of autoantibody profiles in inflammatory arthritis. His work contributes to advancing the understanding of autoimmune diseases and improving patient diagnosis and treatment strategies.

Recent Grants

Grant: Close

ERC Consolidator Grant - The role of complement in the induction of autoimmunity against post-translationally modified proteins.

Open Date: 2017-01-01

Close Date: 2022-01-01

Grant: Close

NWO-VIDI - Understanding the pathological processes of Rheumatoid Arthritis by the analysis of a novel family of auto-antibodies (anti-CarP)

Open Date: 2012-01-01

Close Date: 2017-01-01

Grant: Close

NWO-VENI - Inhibiting the initiators; the role of complement inhibitors in the prevention of autoimmunity

Open Date: 2007-01-01

Close Date: 2010-01-01

Articles (18)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (18)

Peter van Veelen

Leiden University Medical Center

NETHERLANDS

Leendert Trouw

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (18)

Anti-myeloperoxidase IgM B cells in anti-neutrophil cytoplasmic antibody-associated vasculitis

Autoantibodies and therapeutic antibodies against complement factor H

Structural basis for surface activation of the classical complement cascade by the short pentraxin C-reactive protein

Circulating levels of endogenous complement inhibitors correlate inversely with complement consumption in systemic lupus erythematosus

Autoimmune hepatitis displays distinctively high multi-antennary sialylation on plasma N-glycans compared to other liver diseases

Differences in avidity of anti-post-translationally modified protein antibodies in mouse models and rheumatoid arthritis patients: not one-size-fits-all

Complement is activated by elevated IgG3 hexameric platforms and deposits C4b onto distinct antibody domains

Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical phenotype and an HLA class II association

Type 17-specific immune pathways are active in early spondyloarthritis

Host biomarker-based quantitative rapid tests for detection and treatment monitoring of tuberculosis and COVID-19.

Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals.

PTX3 structure determination using a hybrid cryoelectron microscopy and AlphaFold approach offers insights into ligand binding and complement activation.

B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitis

Autoantibodies against specific post-translationally modified proteins are present in patients with lupus and associate with major neuropsychiatric manifestations

Circulating Levels of Anti-C1q and Anti-Factor H Autoantibodies and Their Targets in Normal Pregnancy and Preeclampsia.

Anti-carbamylated protein antibodies positivity and disease activity in Hispanic patients with established rheumatoid arthritis: An observational study

Initial properdin binding contributes to alternative pathway activation at the surface of viable and necrotic cells.

Circulating C1q levels in health and disease, more than just a biomarker

Collaborators (18)

Peter van Veelen

Annemieke Geluk

Cornelis Hokke

Tom Huizinga

Leonie Taams

frederique ponchel

Bart van Hoek

Hans Ulrich Scherer

Jutte J.C. de Vries

Paul J. Hensbergen

Cees van Kooten

Frank Staal

Simone A Joosten

Y K Onno Teng

Thomas H. Sharp

Anna Inkeri Lokki

Noortje de Haan

Michael Eikmans

Make your next move.